“Arecor’s proprietary technology platform to be applied in the development of an ultra-rapid acting insulin to improve quality of life”

Arecor Ltd, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that the Company has filed a Clinical Trial Application (“CTA”) to conduct a Phase I study in Type 1 patients of its ultra-rapid acting insulin product, AT247.   This novel formulation of prandial insulin is designed to deliver an acceleration of insulin absorption post injection.

The study will compare the pharmacokinetic and pharmacodynamic profiles of AT247 to that of Novolog® and FIasp®, as well as assess safety and tolerability, which will be conducted at a clinical site in Austria – an internationally recognised centre of excellence within the field of diabetes research.

Ultra-rapid prandial insulin:

There is a recognised patient need to develop prandial insulins with a faster onset of action than the current state of the art products.  Prandial insulin is used by diabetics to control the rise in blood glucose after eating.  A faster onset of action would enable the more effective management of blood glucose around mealtimes and should lead to better postprandial glycaemic control, reduction in variability, improved HbA1c and allow greater flexibility in the timing of insulin injections.

Sarah Howell, CEO at Arecor, commented:

"We are delighted to be filing a CTA with the Austrian Regulatory Authorities to conduct the first Phase I clinical trial of our innovative ultra-rapid acting insulin. This represents a key and important milestone in the advancement of the Company’s proprietary portfolio for diabetes care.”

“There remains a critical unmet need to develop even faster acting insulins that more closely match a healthy body’s physiological response to blood glucose and should lead to better postprandial glycaemic control, patient compliance and control and ultimately lead to improved health outcomes.  These insulins can also pay a pivotal role in advancing the development of a fully closed loop artificial pancreas system.  I am extremely proud of Arecor’s contribution to developing improved treatments for patients living with debilitating and often life-threatening diseases”.  

RE: THE FORTHCOMING 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Dr Sarah Howell (Chief Executive Officer) and Dr Jan Jezek (Chief Scientific Officer) will be attending the 37th Annual J.P. Morgan Healthcare Conference, being held between January 7-10, 2019 at the Westin St. Francis Hotel, 335 Powell St, San Francisco, CA., US.

To arrange a one-on-one meeting with Arecor’s management team in San Francisco, please contact:

Maggie McConnell, Office Manager/PA

(Tel: +44 (0)1223 426060) (Email: maggie.mcconnell@arecor.com)

 

For more information, please contact:

Dr Sarah Howell

Arecor Limited

Chief Executive officer

Tel: +44 (0) 1223 426060

Email: sarah.howell@arecor.com

Mr Tarquin Edwards

Peckwater PR

Mo: +44 (0) 7879 458 364

Email: tarquin.edwards@peckwaterpr.co.uk

 

About Arecor (www.arecor.com)

Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides.  Arecor's product portfolio also includes:

  • Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
  • Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
  • Stable aqueous glucagon for emergency and artificial pancreas use, and
  • A series of undisclosed pre-clinical programmes.

In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

About ArestatTM

Arecor has significant experience and a proven track record in applying the ArestatTM formulation technology platform to deliver superior biopharmaceutical product profiles across a broad range of proteins, peptides and vaccines.

About Arecor’s Patent Portfolio

Arecor’s technology is protected by 28 patent families, including 26 granted patents.  Arecor has been exploiting its technology in partnerships with pharmaceutical companies, successfully developing superior product profiles, including stable high-concentration antibodies with low viscosity, reformulations of lyophilised or freeze-dried products into stable liquids or stable vaccines that can be used outside the cold chain.